『MPR Weekly Dose』のカバーアート

MPR Weekly Dose

MPR Weekly Dose

著者： MPR Weekly Dose
無料で聴く

このコンテンツについて

 Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news.All rights reserved 衛生・健康的な生活
エピソード
  • MPR Weekly Dose Podcast #251 — Qivigy for Primary Humoral Immunodeficiency; Near Vision Eyedrops; Tremfya Expanded; Meth Intoxication Tx; Alzheimer Disease Tx Fast Tracked

    MPR Weekly Dose Podcast #251 — Qivigy for Primary Humoral Immunodeficiency; Near Vision Eyedrops; Tremfya Expanded; Meth Intoxication Tx; Alzheimer Disease Tx Fast Tracked
    2025/10/03
    New treatment approved for primary humoral immunodeficiency; eyedrops now available to improve near vision; Tremfya approval expanded to include pediatric plaque psoriasis, psoriatic arthritis; FDA fast tracks treatments for methamphetamine intoxication, Alzheimer disease.
    続きを読む 一部表示
    11 分
  • MPR Weekly Dose Podcast #250 — Changes to MMRV Recs; Trump Admin Links Acetaminophen to Autism; Forzinity Accelerated Approval; Huntington Disease Breakthrough; SC Formulation of Keytruda

    MPR Weekly Dose Podcast #250 — Changes to MMRV Recs; Trump Admin Links Acetaminophen to Autism; Forzinity Accelerated Approval; Huntington Disease Breakthrough; SC Formulation of Keytruda
    2025/09/26

    The CDC recommends changes to MMRV vaccine use; Trump administration claims acetaminophen linked to autism; first Barth syndrome treatment gets green light; gene therapy looks promising for Huntington disease; and a new SC formulation of Keytruda gains approval.
    続きを読む 一部表示
    16 分
  • MPR Weekly Dose Podcast #249 — Device for Asherman Syndrome; Novel Oral GLP-1 Trial Results; Nasal Spray for Edema; Capvaxive in Adolescents; Ocaliva Withdrawn

    MPR Weekly Dose Podcast #249 — Device for Asherman Syndrome; Novel Oral GLP-1 Trial Results; Nasal Spray for Edema; Capvaxive in Adolescents; Ocaliva Withdrawn
    2025/09/19

    New device approved to prevent intrauterine adhesions; oral GLP-1 receptor agonists assessed in head to head trial; nasal spray formulation of bumetanide gains approval; Capvaxive elicits immune response in children aged 2 to 17 years; and a primary biliary cholangitis treatment is withdrawn from the market.
    続きを読む 一部表示
    12 分
まだレビューはありません